Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07117318
NA

Rectal NSAIDs With/Without PD Stent for PEP Prevention

Sponsor: Air Force Military Medical University, China

View on ClinicalTrials.gov

Summary

Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stent (PDS) placement were demonstrated to be effective strategyies to reduce PEP incidences, particlularly in high-risk patients for post-ERCP pancreatitis (PEP). Rectal NSAIDs were easy-to-use and safe, while PDS placement were technically complex and carried higher risks of adverse events. A previous network meta-analysis suggested rectal NSAIDs in combination with PDS placement did not differ from rectal NSAIDs alone in PEP prevention. To invesigate if rectal NSAIDs alone could obivate the need of PDS placement, a recent trial from Elmunzer et al. conducted a randomized trial to investigate if rectal NSAIDs alone was non-inferior to the combination of NSAIDs with PDS in high-risk patients. The trial found that the PEP incidence rate in combination group was significantly lower than that in NSAIDs alone group. However, post-hoc analysis of the study suggested that the combination strategy conferred significant benefits only in high-risk patients with pancreatic duct (PD) wire passage, but not in those with other risk factors. Therefore, we hypothesized that rectal NSAIDs alone may obivate the need of PDS in high-risk patients without PD wire passages. Here, we conducted a multicenter, randomized and non-inferiority trial to investigate whether rectal NSAIDs alone is non-inferior to NSAIDs plus PDS placement in high-risk patients without PD wire passages.

Official title: Rectal Non-steroid Anti-inflammatory Drugs With or Without Prophylactic Pancreatic Duct Stent for Prevention of Post-ERCP Pancreatitis: a Multicenter, Randomized, Non-inferiority Trial

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

1278

Start Date

2025-07-01

Completion Date

2028-06-01

Last Updated

2025-12-03

Healthy Volunteers

No

Interventions

DRUG

NSAIDs

All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure

DEVICE

NSAIDs plus PDS

All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure. When eligibility is met, PDS placement will be performed by ERCP colonoscopists.

Locations (15)

The first medical center, Chinese PLA General Hospital

Beijing, Beijing Municipality, China

Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Department of Gastroenterology, Fujian Medical University Xiamen Humanity Hospital

Xiamen, Fujian, China

Harbin Medical University Affiliated Fourth Hospital

Harbin, Heilongjiang, China

The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Department of Gastroenterology, Huaihe Hospital of Henan University

Kaifeng, Henan, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

986 Hospital of Xijing Hospital

Xi'an, Shaanxi, China

Xijing of Digestive Diseases

Xi'an, Shaanxi, China

Department of Gastroenterology, The 960th Hospital of the PLA

Jinan, Shandong, China

Shandong Provincial Third Hospital

Jinan, Shandong, China

Department of Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University

Shanghai, Shanghai Municipality, China

Affiliated Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

the First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China